Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer

Chest

Volumn 114, Issue 2, 1998, Pages 593-604

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Non small cell lung cancer; Prognosis; Questionnaire; Treatment

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0031841106     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.114.2.593     Document Type: Article

References (53)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin 1997; 48:6-29
2. Ginsberg RJ, Vokes EE, Raben A. Non-small-cell lung cancer. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997; 858-911
3. Mackillop WJ, O'Sullivan B, Ward GK. Non-small cell lung cancer: how oncologists want to be treated. Int J Radiat Oncol Biol Phys 1987; 13:929-34
4. Palmer MJ, O'Sullivan B, Steele R, et al. Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiother Oncol 1990; 19:17-28
5. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? another look at the assessment of non-small-cell lung cancer. J Clin Oncol 1995; 13:1904-11
6. Brundage MD, Groome PA, Feldman-Stewart D, et al. Decision analysis in locally advanced non-small-cell lung cancer: is it useful? J Clin Oncol 1997; 15:873-83
7. Ruckdeschel JC, Wagner H, Robinson L. Locally advanced lung cancer: controversies in management. Adv Oncol 1996; 12:22-28
8. Mackillop WJ, Ward GK, O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer 1986; 54:661-67
9. Greenberg ER, Chute CG, Stukel T, et al. Social and economical factors in the choice of lung cancer treatment. N Engl J Med 1988; 318:612-17
10. Ginsberg RJ, Rubinstein L. The comparison of limited resection to lobectomy for T1N0 non-small cell lung cancer: LCSG 821. Chest 1994; 106(suppl):318S-19S
11. Livingston RB. Therapeutic options for non-small cell lung cancer. New Persp Cancer Diag Manage 1996; 4:16-21
12. Nesbitt JC, Putnam JB Jr, Walsh GL, et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995; 60:466-72
13. Kaskowitz L, Graham MV, Emami B, et al. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993; 27:517-23
14. Weisenburger TH. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung: LSCG 773. Chest 1994; 106(suppl): 297S-301S
15. Stewart LA, Burdett A, Souhami RL. Postoperative radiotherapy (PORT) in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTS) [abstract]. Proc Am Soc Clin Oncol 1998; 17:457A
16. Masters GA, Vokes EE, Golomb HM. Advances in the detection and management of early-stage non-small cell lung cancer. Adv Oncol 1996; 12:16-21
17. Lad T. The comparison of CAP chemotherapy and radiotherapy to radiotherapy alone for resected lung cancer with positive margin or involved highest sampled paratracheal node (stage IIIA): LCSG 791. Chest 1994; 106(suppl):302S-06S
18. Ohta M, Tsuchiya R, Shimoyama M, et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer: results of a randomized prospective study: the Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 1993; 106:703-08
19. Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330:153-58
20. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86:673-80
21. Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992; 10:580-86
22. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55:1365-74
23. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13:1880-92
24. Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10:1237-44
25. Dillman R, Seagren S, Prospert K, et al. A randomized trial of induction chemotherapy plus high-dose radiation vs radiation alone in stage III NSCLC. N Engl J Med 1990; 323:940-45
26. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-15
27. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83:417-23
28. Schaake-Koning C, Vandan Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 563-65
29. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15:2996-3018
30. Hudes R, Langer C, Movsas B, et al. Induction paclitaxel (Taxol) and carboplatin (CBDCA) followed by concurrent chemoradiotherapy (TRT-CT) in unresectable, locally advanced non-small cell lung carcinoma (NSCLC): report of FCCC 94-001 [abstract 1609]. Proc Am Soc Clin Oncol 1997; 16:448a
31. Belani CP, Aisner J, Day R, et al. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC): three year follow-up [abstract 1608]. Proc Am Soc Clin Oncol 1997; 16:448a
32. Choy H, Akerley W, Safran H, et al. Phase II trial of weekly paclitaxel, carboplatin and concurrent radiation therapy for locally advanced non-small cell lung cancer (NSCLC) [abstract 1637]. Proc Am Soc Clin Oncol 1997; 16:456a
33. Niell HB, Miller AA, Kumar P, et al. Phase I/II trial of paclitaxel (TAX), cisplatin (DDP) and radiation therapy for stage III non-small cell lung cancer (NSCLC) [abstract 1606]. Proc Am Soc Clin Oncol 1997; 16:447a
34. Damstrup L, Poulsen HS. Review of the curative role of radiotherapy in the treatment of non-small cell lung cancer. Lung Cancer 1994; 11:153-78
35. Masters GA, Vokes EE. Should non-small cell carcinoma of the lung be treated with chemotherapy? pro: chemotherapy is for non-small cell lung cancer [editorial]. Am J Respir Crit Care Med 1995; 151:1285-87
36. Carney DN. Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 1996; 23(suppl 16):71-75
37. Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85:388-94
38. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:384-88
39. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70:384-87
40. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12:1238-44
41. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12:1232-37
42. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1535-40
43. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1821-26
44. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10:16-20
45. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14:115-19
46. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360-67
47. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) trial [abstract 1145]. Proc Am Soc Clin Oncol 1996; 15:382
48. Johnson DH, Paul HM, Hande KR, et al. Paclitaxel plus carboplatin for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996; 14:2054-60
49. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13:1860-70
50. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11:1866-72
51. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12:199-220
52. Cella D, Fairclough DL, Bonomi PB, et al. Quality of life (QOL) in advanced non-small cell lung cancer (NSCLC): results from Eastern Cooperative Oncology Group (ECOG) study E5592 [abstract 4]. Proc Am Soc Clin Oncol 1997; 16:2a
53. Giaccone G, Splinter TAW, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1998; 16:2133-41